Prognostic value of Ki67 in phyllodes tumor of the breast: A systematic review and meta‑analysis

Refai,Fahd

doi:10.3892/etm.2024.12747

Prognostic value of Ki67 in phyllodes tumor of the breast: A systematic review and meta‑analysis

Authors:
- Fahd Refai
View Affiliations

Affiliations: Department of Pathology, Faculty of Medicine, King Abdulaziz University and King Abdulaziz University Hospital, Jeddah 25668, Saudi Arabia
Published online on: October 15, 2024 https://doi.org/10.3892/etm.2024.12747
Article Number: 457
Copyright: © Refai . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous clinicopathological features have been examined as predictive factors for adverse outcomes in patients with phyllodes tumor (PT) of the breast, but there are still no definitive predictive markers to guide management, despite the persistent risk of recurrence, even in benign disease. Whether Ki67 has prognostic value in PT remains uncertain. Therefore, a systematic review and meta‑analysis were performed to examine whether Ki67 is associated with adverse clinical outcomes, particularly recurrence, in patients with PT. The PubMed/MEDLINE, Web of Science, Scopus, Embase and Cochrane Library databases were searched from inception to July 2024. Study characteristics and outcomes (recurrence and overall survival) according to Ki67 status were extracted from each eligible study, and pooled log odds ratios (OR) with 95% CI were derived using a random‑effects model. A total of five studies comprising 280 cases were eligible for inclusion. The adverse outcome rate for the Ki67^high (Ki67 >10 or >11.2%) population was 28.7% (95% CI, 20.1‑38.6%), while the adverse outcome rate for the Ki67^low population was 9.4% (95% CI, 5.4‑13.5%). Ki67^high was associated with an increased odds of an adverse outcome [log OR, 1.26 (95% CI, 0.38‑2.15; P=0.005)] compared with a Ki67^low status. All five studies scored 8 points on the Newcastle‑Ottawa Scale, equivalent to ‘good’ quality according to Agency for Healthcare Research and Quality standards, and no significant publication bias was noted. This was the first meta‑analysis of the predictive value of Ki67 in PT of the breast. A relatively high Ki67 index (>10%) is associated with recurrence. It is timely to re‑evaluate the prognostic value of Ki67 in large retrospective cohorts with long follow‑up to firmly establish whether it could contribute to identifying patients at risk of recurrence, particularly those with histologically benign disease. Doing so could impact clinical practice by refining follow‑up recommendations based on quality evidence.

View Figures

View References

1	Lissidini G, Mule A, Santoro A, Papa G, Nicosia L, Cassano E, Ashoor AA, Veronesi P, Pantanowitz L, Hornick JL and Rossi ED: Malignant phyllodes tumor of the breast: A systematic review. Pathologica. 114:111–120. 2022.PubMed/NCBI View Article : Google Scholar
2	Rakha EA and Ellis IO: Phyllodes Tumor of the Breast. In: Textbook of Uncommon Cancer. Raghavan D, Blanke CD, Johnson DH, Moots PL, Reaman GH, Rose PG and Sekeres MA (eds). Wiley-Blackwell, Hoboken, NJ, p. 243-56, 2012.
3	Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, Calvo JP, Dabbs DJ, Ellis IO, Eusebi V, et al: Phyllodes tumours of the breast: A consensus review. Histopathology. 68:5–21. 2016.PubMed/NCBI View Article : Google Scholar
4	Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, et al: The 2019 World Health Organization classification of tumours of the breast. Histopathology. 77:181–185. 2020.PubMed/NCBI View Article : Google Scholar
5	Yu CY, Huang TW and Tam KW: Management of phyllodes tumor: A systematic review and meta-analysis of real-world evidence. Int J Surg. 107(106969)2022.PubMed/NCBI View Article : Google Scholar
6	Tan PH, Thike AA, Tan WJ, Thu MM, Busmanis I, Li H, Chay WY and Tan MH: Phyllodes Tumour Network Singapore. Predicting clinical behaviour of breast phyllodes tumours: A nomogram based on histological criteria and surgical margins. J Clin Pathol. 65:69–76. 2012.PubMed/NCBI View Article : Google Scholar
7	Bogach J, Shakeel S, Wright FC and Hong NJL: Phyllodes Tumors: A scoping review of the literature. Ann Surg Oncol. 29:446–459. 2022.PubMed/NCBI View Article : Google Scholar
8	Lim RS, Cordeiro E, Lau J, Lim A, Roberts A and Seely J: Phyllodes tumors-the predictors and detection of recurrence. Can Assoc Radiol J. 72:251–257. 2021.PubMed/NCBI View Article : Google Scholar
9	Lashen AG, Toss MS, Ghannam SF, Makhlouf S, Green A, Mongan NP and Rakha E: Expression, assessment and significance of Ki67 expression in breast cancer: An update. J Clin Pathol. 76:357–364. 2023.PubMed/NCBI View Article : Google Scholar
10	Finkelman BS, Zhang H, Hicks DG and Turner BM: The Evolution of Ki-67 and Breast Carcinoma: Past observations, present directions, and future considerations. Cancers (Basel). 15(808)2023.PubMed/NCBI View Article : Google Scholar
11	Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, Pederzoli P, Scarpa A and Falconi M: Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer. 48:1608–1615. 2012.PubMed/NCBI View Article : Google Scholar
12	La Rosa S: Diagnostic, prognostic, and predictive role of Ki67 proliferative index in neuroendocrine and endocrine neoplasms: Past, present, and future. Endocr Pathol. 34:79–97. 2023.PubMed/NCBI View Article : Google Scholar
13	Yamaguchi T, Fujimori T, Tomita S, Ichikawa K, Mitomi H, Ohno K, Shida Y and Kato H: Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence. Diagn Pathol. 8(65)2013.PubMed/NCBI View Article : Google Scholar
14	Tse GM, Niu Y and Shi HJ: Phyllodes tumor of the breast: An update. Breast Cancer. 17:29–34. 2010.PubMed/NCBI View Article : Google Scholar
15	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View Article : Google Scholar
16	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010.PubMed/NCBI View Article : Google Scholar
17	Love J, Selker R, Marsman M, Jamil T, Dropmann D, Verhagen J, Ly A, Gronau QF, Šmíra M, Epskamp S, et al: JASP: Graphical statistical software for common statistical designs. Journal of Statistical Software. 88:1–17. 2019.
18	Kuijper A, de Vos RA, Lagendijk JH, van der Wall E and van Diest PJ: Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors. Am J Clin Pathol. 123:690–698. 2005.PubMed/NCBI
19	Kuijper A, van der Groep P, van der Wall E and van Diest PJ: Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast. Breast Cancer Res. 7:R808–R818. 2005.PubMed/NCBI View Article : Google Scholar
20	Chan YJ, Chen BF, Chang CL, Yang TL and Fan CC: Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast. J Chin Med Assoc. 67:3–8. 2004.PubMed/NCBI
21	Niezabitowski A, Lackowska B, Rys J, Kruczak A, Kowalska T, Mitus J, Reinfuss M and Markiewicz D: Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: Immunohistochemical and flow cytometric study of 118 cases. Breast Cancer Res Treat. 65:77–85. 2001.PubMed/NCBI View Article : Google Scholar
22	Shpitz B, Bomstein Y, Sternberg A, Klein E, Tiomkin V, Kaufman A, Groisman G and Bernheim J: Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. J Surg Oncol. 79:86–92. 2002.PubMed/NCBI View Article : Google Scholar
23	Yonemori K, Hasegawa T, Shimizu C, Shibata T, Matsumoto K, Kouno T, Ando M, Katsumata N and Fujiwara Y: Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Pathol Res Pract. 202:705–712. 2006.PubMed/NCBI View Article : Google Scholar
24	Sain B, Gupta A, Ghose A, Halder S, Mukherjee V, Bhattacharya S, Mondal RR, Sen AN, Saha B, Roy S and Boussios S: Clinico-Pathological factors determining recurrence of phyllodes tumors of the breast: The 25-year experience at a tertiary cancer centre. J Pers Med. 13(866)2023.PubMed/NCBI View Article : Google Scholar
25	McCarthy E, Kavanagh J, O'Donoghue Y, McCormack E, D'Arcy C and O'Keeffe SA: Phyllodes tumours of the breast: Radiological presentation, management and follow-up. Br J Radiol. 87(20140239)2014.PubMed/NCBI View Article : Google Scholar
26	Chng TW, Lee JY, Lee CS, Li H, Tan MH and Tan PH: Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours: An Australian cohort. J Clin Pathol. 69:1124–1126. 2016.PubMed/NCBI View Article : Google Scholar
27	Choi JE, Kang SH, Tan PH and Bae YK: Recurrence prediction for breast phyllodes tumours: Validation of the Singapore nomogram in Korean women. J Clin Pathol. 75:159–163. 2022.PubMed/NCBI View Article : Google Scholar
28	Nishimura R, Tan PH, Thike AA, Tan MH, Taira N, Li HH and Ohsumi S: Utility of the Singapore nomogram for predicting recurrence-free survival in Japanese women with breast phyllodes tumours. J Clin Pathol. 67:748–750. 2014.PubMed/NCBI View Article : Google Scholar